Comprehensive review of potential drugs with anti|pulmonary ...

Comprehensive review of potential drugs with anti-pulmonary ...

This systematic review evaluates the antifibrotic potential of non-antifibrotic agents and investigational drugs. Abstract. Pulmonary fibrosis is a chronic and ...

Comprehensive review of potential drugs with anti-pulmonary ...

Comprehensive review of potential drugs with anti-pulmonary fibrosis properties ... Keywords: Drug target; Lung injury; New therapies; Potential drug; Pulmonary ...

Comprehensive review of potential drugs with anti-pulmonary ...

This review aims to provide an updated overview of current and future drug interventions for idiopathic pulmonary fibrosis, and to summarize possible targets of ...

Comprehensive review of potential drugs with anti-pulmonary ...

Comprehensive review of potential drugs with anti-pulmonary fibrosis properties ; Journal: Biomedicine & Pharmacotherapy, 2024, p. 116282 ; Publisher: ...

Comprehensive review of potential drugs with anti-pulmonary ...

This review aims to provide an updated overview of current and future drug interventions for idiopathic pulmonary fibrosis, and to summarize ...

Current and Future Treatment Landscape for Idiopathic Pulmonary ...

The pharmacotherapeutic landscape for IPF is moving forward with a number of new drugs currently in clinical development, mostly in phase I and II trials.

Drug therapies for treatment of idiopathic pulmonary fibrosis

However, studies in regards to the costs associated with efficiency of IPF medications are scarce, mostly focused on few specific drugs with ...

Advancing Treatment Strategies: A Comprehensive Review of Drug ...

Nanoparticle-based drug delivery systems, inhaled corticosteroids (ICSs), novel biologicals, gene therapy, and personalized medicine have emerged as promising ...

Pharmacotherapy for idiopathic pulmonary fibrosis

Treatment with antifibrotic agents pirfenidone and nintedanib · Antiacid treatment for IPF · N-acetylcysteine treatment for IPF · Other medications tried for IPF.

The current landscape of antifibrotic therapy across different organs

However, in this review we will only consider as potential anti-fibrotic agents ... Intralesional cryotherapy for treatment of keloid scars: a prospective study.

Anti-tuberculosis treatment strategies and drug development - Nature

The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. ... anti-TB agents ...

Host-directed therapies in pulmonary tuberculosis: Updates on anti ...

used a single anti-TB drug (isoniazid or ethambutol), whereas Duta NK et al. employed four drugs, which may have masked a possible role of metformin in ...

Efficacy of anti-tuberculosis drugs for the treatment of latent ... - Nature

Efficacy of anti-tuberculosis drugs for the treatment of latent tuberculosis infection: a systematic review and network meta-analysis. Panida ...

Classification of antituberculosis drugs: a new proposal based on ...

Similarly, an accompanying drug should be replaced by another with a similar action. Classification of anti-TB drugs and potential for an update. To build an ...

Potential Repurposed Drug Candidates for Tuberculosis Treatment

The Impact of First-Line Anti-Tubercular Drugs' Pharmacokinetics on Treatment Outcome: A Systematic Review. ... a potential anti-tubercular drug ...

Drug-Induced Interstitial Lung Disease: A Systematic Review - MDPI

DIILD prognosis varies between drugs and different studies. Complete recovery is possible following dose reduction, drug withdrawal and/or concomitant GC use [ ...

A review of formulations and preclinical studies of inhaled rifampicin ...

Pulmonary delivery of anti-TB drugs is expected to deliver high drug concentrations at the desired site, i.e., to the granulomatous TB lesions ...

Treatment for TB Disease - CDC

... potential for drug-drug interactions. ... TB treatment regimens vary in the duration of the regimen, the types of anti-TB drugs prescribed, and the dose and ...

Interstitial Lung Disease: A Review - JAMA Network

However, both drugs increased FVC (cyclophosphamide by a mean [SD] of 99 [329] mL and rituximab by a mean [SD] of 97 [234] mL) and improved ...

Repurposing approved non-oncology drugs for cancer therapy

Many methods were used to explore the probable anticancer function of non-cancerous drugs. For drug repurposing of non-oncology medications many ...